Beta Bionics (BBNX) reported a Q4 net loss late Tuesday of $2.72 per diluted share.
The company did not provide a year-ago per-share figure.
Analysts polled by Factset expected a loss of $0.90.
Net sales for the quarter ended Dec. 31 were $20.4 million, up from $8.4 million a year earlier.
Analysts surveyed by Factset expected $20.2 million.
The company set full-year 2025 revenue guidance between $80 million and $85 million.
Analysts polled by Factset expect $85.1 million.
Beta Bionics completed its initial public offering on Jan. 30, listing on the Nasdaq Global Market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。